1. Home
  2. PRTA vs JBSS Comparison

PRTA vs JBSS Comparison

Compare PRTA & JBSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.54

Market Cap

458.4M

Sector

Health Care

ML Signal

N/A

Logo John B. Sanfilippo & Son Inc.

JBSS

John B. Sanfilippo & Son Inc.

N/A

Current Price

$66.48

Market Cap

846.7M

ML Signal

N/A

Company Overview

Basic Information
Metric
PRTA
JBSS
Founded
2012
1959
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
458.4M
846.7M
IPO Year
2013
1994

Fundamental Metrics

Financial Performance
Metric
PRTA
JBSS
Price
$8.54
$66.48
Analyst Decision
Hold
Buy
Analyst Count
6
2
Target Price
$21.40
★ $100.00
AVG Volume (30 Days)
★ 337.4K
77.2K
Earning Date
11-05-2026
10-28-2026
Dividend Yield
N/A
★ 6.77%
EPS Growth
N/A
★ 4.57
EPS
0.26
★ 5.26
Revenue
$814,000.00
★ $1,175,673,000.00
Revenue This Year
$758.69
$0.97
Revenue Next Year
N/A
$3.63
P/E Ratio
$33.27
★ $12.88
Revenue Growth
N/A
★ 6.18
52 Week Low
$7.73
$59.07
52 Week High
$11.80
$92.08

Technical Indicators

Market Signals
Indicator
PRTA
JBSS
Relative Strength Index (RSI) 44.91 29.93
Support Level $8.12 N/A
Resistance Level $9.29 $84.75
Average True Range (ATR) 0.38 1.54
MACD -0.02 0.29
Stochastic Oscillator 41.50 11.37

Price Performance

Historical Comparison
PRTA
JBSS

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About JBSS John B. Sanfilippo & Son Inc.

John B Sanfilippo & Son Inc is processors and distributors of peanuts, pecans, cashews, walnuts, almonds and other nuts in the United States. It also manufacture and distribute a portfolio of snack and nutrition bars, and market and distribute, and in some cases, manufacture or process, a diverse product line of other food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snack and trail mixes, granola, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products. It mainly sell its products under a variety of private brand names, as well as under its Fisher, Orchard Valley Harvest, Squirrel Brand and Southern Style Nuts brand names. It operate in a single reporting segment.

Share on Social Networks: